Maintenance notice in CEST time zone (1:00 - 3:30 AM May 17, 2026): Our website is scheduled for maintenance. The website will be available, but some functions may experience errors. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.201
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 19171-19-8 | Product Number: P2074
Pomalidomide
×
Purity: >98.0%(HPLC)
Synonyms:
- 3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
Shipping Information
|
|---|---|---|---|---|---|
| 25MG |
€100.00
|
1 | 37 |
|
|
| 100MG |
€303.00
|
1 | ≥100 |
|
* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)
| Product Number | P2074 |
Purity / Analysis Method 
|
>98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__1__3H__1__1N__3O__4 = 273.25 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| Packaging and Container
|
100MG-Glass Bottle with Plastic Insert (View image), 25MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 19171-19-8 |
| Reaxys Registry Number | 8340987 |
| PubChem Substance ID | 253660183 |
| Merck Index (14) | 135 |
| MDL Number | MFCD12756407 |
Specifications
| Appearance | White to Yellow to Green powder to crystaline |
| Purity(HPLC) | min. 98.0 area% |
Properties (reference)
| Melting Point | 313 °C(dec.) |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H361 : Suspected of damaging fertility or the unborn child. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
Related Laws:
| RTECS# | NR3397905 |
Transport Information:
| HS Number | 2925199590 |
Application
A Potent Anti-Myeloma, Anti-Inflammatory and Immunomodulatory Agent, Pomalicomide
Pomalidomide (CC-4047), a thalidomide analog, is an immunomodulatory agent with numerous effects on the body's immune system, and has potent anti-myeloma and anti-inflammatory activities in vitro and in vivo. Pomalidomide inhibits the cytokines tumor necrosis factor-α (TNF-α), interleukins (IL) 1β, 6, 12, and granulocyte macrophage-colony stimulating factor (GM-CSF).
References
- Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity
- Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells
- The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
- Pharmacological properties of thalidomide and its analogues
- Pomalidomide therapy for myeloma
- Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.